Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells

Leukemia Research

Volumn 30, Issue 3, 2006, Pages 296-302

  Lu, C ^a   Hassan, H T ^a,b  

^a UNIVERSITY OF LINCOLN   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

AML; Apoptosis; Bcl 2; CD34+; Chemotherapy; Cytarabine; Daunorubicin; Elderly; Flow cytometry; Myeloid leukaemia

Indexed keywords

CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; LIPOCORTIN 5; PROTEIN BCL 2; STEM CELL FACTOR; STEM CELL FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CD34 SELECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LOW DRUG DOSE; NECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLAST CRISIS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; CYTARABINE; DAUNORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; P-GLYCOPROTEIN; PILOT PROJECTS; RECEPTORS, CYTOKINE; STEM CELL FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 30144442793     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.026     Document Type: Article

References (39)

1. H.T. Hassan, K. Gutensohn, A.R. Zander, and P. Kuehnl CD34 positive cell sorting and enrichment: applications in blood banking and transplantation D. Recktenwald A. Radbruch Cell separation methods and applications 1998 Marcel Dekker Inc. New York 283 292
2. J.E. Godwin, and S.E. Smith Acute myeloid leukaemia in the older patient Crit Rev Oncol Hematol 48S 2003 S17 S26
3. J.L. Harousseuau Acute myeloid leukaemia in the elderly Blood Rev 12 1988 145 153
4. H.T. Hassan, and J.K.H. Rees Relation between age and blast cell differentiation in acute myeloid leukaemia patients Oncology 47 1990 439 442
5. A. Venditti, G. Del Poeta, F. Buccisano, A. Tamburini, M.C. Cox-Froncillo, and A. Bruno Biological features of acute myeloid leukaemia in the elderly Blood 92 2 1988 697 705
6. S.Y. Huang, J.L. Tang, S.T. Jou, W. Tsay, C.H. Hu, and D.T. Lin Minimally differentiated acute myeloid leukaemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years Leukaemia 13 1999 1506 1511
7. L. Suarez, B. Vidriales, J. Garcia-Larana, A. Lopez, R. Martinez, and V. Martin-Reina Multi-parametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukaemia Haematologica 86 2001 1287 1295
8. D. Grimwade, E. Walker, G. Harrison, J.K.H. Rees, and A.K. Burnett The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukaemia (AML): analysis of 1065 patients entered into tyjyhe UK MRC AMasL11 trial Blood 98 2001 1312 1320
9. C.P. Leith, K.J. Kopecky, and J.-M. Chen Frequency and clinical significance of the expression of the multi-drug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukaemia A Southwest Oncology Group study Blood 94 1999 1086 1099
10. A. Wahlin, B. Markevarn, I. Golovleva, and M. Nilsson Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia Br J Hematol 115 2001 25 33
11. D.L. Stirewalt, K.J. Kopecky, and Meschinchi S FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukaemia Blood 97 2001 3589 3595
12. S. Schnittger, C. Schoch, M. Dugas, W. Kern, P. Staib, and C. Wuchter Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukaemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66
13. C. Thiede, C. Steudel, B. Morh, M. Schaich, U. Schakel, and U. Platzbecker Analysis of FLt2-activating mutations in 979 patients with acute myelogenous leukaemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
14. D.L. Stirewalt, S. Meshinchi, and J.P. Radich Molecular targets in acute myelogenous leukaemia Blood Rev 17 2003 15 23
15. T. Kindler, F. Breitenbuecher, A. Marx, G. Hess, H. Gscaidmeier, and H. Gamm Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory secondary AML Blood 101 2003 2960 2962
16. M. Schittenhelm, O. Aichele, S.M. Krober, T. Brummendorf, L. Kanz, and C. Denzlinger Complete remission of third recurrence of AML after treatment with imatinib (STI-571) Leuk Lymphoma 44 2003 1251 1253
17. T. Kindler, F. Breitenbuecher, A. Marx, J. Beck, G. Hess, and K. Weinkauf Efficacy and safety of imatinib in adult patients with c-kit-positive AML Blood 103 2004 3644 3654
18. B.D. Smith, M. Levis, M. Beram, F. Giles, H. Kantarjian, and K. Berg Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed acute myeloid leukaemia Blood 103 2004 2669 2676
19. W. Fiedler, R. Mesters, H. Tinnefeld, S. Loges, P. Staib, and U. Duhrsen A phase 2 clinical study of SU5416 in patients with refractory AML Blood 102 2003 2763 2767
20. A.M. O'Farrell, H.A. Yuen, B. Smolich, A.L. Hannah, S.G. Louie, and W. Hong Effect of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukaemia Leuk Res 28 2004 679 689
21. S. Schwartz, A. Heinecke, M. Zimmermann, U. Creutzig, C. schoch, and J. Harbott Expression of c-kit receptor (CD117) is a feature of almost all subtypes of de novo AML, including cytogenetically good-risk AML and lacks prognostic significance Leuk Lymphoma 34 1999 85 94
22. A. Macedo, A. Orfao, A. Martinez, M.B. Vidriales, B. Valverde, and M.C. Lopez-Berges Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease Br J Hematol 89 1995 338 341
23. M.P. Scolnik, R. Morilla, M.M. de Bracco, D. Catovsky, and E. Matutes CD34 and Cd117 are over-expressed in AML and may be valuable to detect minimal residual disease Leuk Res 26 2002 615 619
24. M. Graf, K. Hecht, S. Reif, R. Pelka-Fleischer, K. Pfister, and H. Schmetzer Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukaemia (AML): implications for future therapeutic strategies Eur J Hematol 72 2004 89 106
25. H. Chang, F. Slama, Q.L. Yi, B. Patterson, B. Brien, and M.D. Minden Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukaemia Leuk Res 28 2004 43 48
26. R.S. Care, P.J. Valk, A.C. Goodeve, F.M. Abu-Duhier, W.M. Geertsma-Kleinekoort, and G.A. Wilson Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias Br J Hematol 121 2003 775 777
27. N. Ahmed, L. Laverick, J. Sammons, K. Baumforth, and H.T. Hassan Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down regulation of bcl-2 in human myeloid leukaemia CD34 positive cells Leuk Res 23 1999 741 749
28. N. Ahmed, L. Laverick, J. Sammons, H. Zhang, D. Maslin, and H.T. Hassan Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34 positive CD7 negative resistant cells Anticancer Res 21 2001 3519 3524
29. H.T. Hassan, S. Grell, U. Borrmann-Danso, and M. Freund Interferon-alpha enhances the cytotoxic and cytostatic activities of chemotherapeutic drugs in human myeloid leukaemia cells J Interferon Cytokine Res 16 1995 139 146
30. M.R. Litzow The therapy of relapsed acute leukaemia in adults Blood Rev 18 2004 39 63
31. J.M. Norgard, L.H. Olesen, and P. Hokland Changing picture of cellular drug resistance in human leukaemia Crit Rev Oncol Hematol 50 2004 39 49
32. H.T. Hassan, and M. Freund Stem cell factor protects CD34-positive human myeloid leukaemia cells from chemotherapy-induced apoptosis R. Pieters Drug resistance in leukaemia and lymphoma 1995 Gordon & Breach Science Publishers Harwood 123 129
33. J. Liu Yin, K. Wheatley, J.K.H. Rees, and A.K. Burnett Comparison of sequential versus standard chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed AML: results of the UK MRC AML-R trial Br J Hematol 113 2001 713 726
34. P. Greenberg, R. Advani, M. Tallman, L. Letendre, H. Saba, and K. Dugan Treatment of refractory/relapsed AML with pSC883 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs. MEC: randomised phase III trial (E2995) Blood 94 1999 383a
35. M.R. Baer, S.L. Goerge, and R.K. Dodge Phase III study of the MDR modulator: PSC-883 in previously untreated patients 60 years of age and older with AML: cancer and leukaemia group B study 9720 Blood 100 2002 1224 1232
36. G. Vario, K.M. Innes, and J.M. Adams Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival Oncogene 13 1996 1159 1511
37. J. Yang, X. Lui, K. Bhalla, C.N. Kim, A.M. Ibrado, and J. Caj Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked Science 275 1997 1129 1132
38. G. Marcucci, J.C. Byrd, G. Dai, M.J. Klisovic, P.J. Kourlas, and D.C. Young Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukaemia Blood 101 2003 425 432
39. G. Marcucci, J.C. Byrd, G. Dai, M.J. Klisovic, P.J. Kourlas, and D.C. Young Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukaemia Blood 102 2003 Abstract 1398